Comparison of the effects of etomidate, ketamine, sodium thiopental, and midazolam on the mortality of patients with COVID-19 requiring intubation

• Published in: Medical journal of the Islamic Republic of Iran Vol. 35; p. 49
• Main Authors: Edalatkhah, Abbas, Kazemi, Mohammad Reza, Samadi Khorshidi, Fatemeh, Akhoundimeybodi, Zohreh, Seyedhosseini, Seyed Mohsen, Rostami, Soheila, Hosseini, Bibi Vaghihe, Akhondi, Zohreh, Ghelmani, Yaser
• Format: Journal Article
• Language: English
• Published: Iran Iran University of Medical Sciences 2021
• Subjects: Original; COVID-19; Intubation; Mortality; Etomidate
• DOI: 10.47176/mjiri.35.49
• EISSN: 2251-6840
• ISSN: 1016-1430

Among the medications administered for the management of COVID-19 patients, the induction drugs used for intubation have received little attention. The aim of this study was to compare the effect of induction drugs on the mortality of patients with COVID-19 requiring intubation.
In this retrospective study, all patients who were admitted to Shahid Sadoughi and Shahid Rahnemoun hospitals in Yazd from February to March 2020 with definitive diagnosis of COVID-19 and needed intubation were enrolled. Patients were divided into 4 groups based on the type of drugs used in intubation, and mortality rate was assessed at the end of the first, second, fourth, and seventh days of the study. Statistical analyses were performed using SPSS 20 and P values <.05 was considered significant.
In this study, 76 patients were examined. Patients were divided into 4 groups, of which 21 were in etomidate group, 8 in ketamine group, 21 in sodium thiopental group, and 35 in midazolam group. Mortality rate in these 4 groups was 25%, 12.5%, 14.3%, and 14.3% (p=0.822), respectively at the end of the first day after intubation; it was 83.3%, 12.5%, 28.6%, and 25.7% (p=0.001), respectively, at the end of the second day; it was 83.3%, 12.5%, 42.9%, and 42.9% (p=0.015), respectively, until the end of the fourth day; it was 100%, 25%, 61.9%, and 65.7% (p=0.007), respectively, until the end of the seventh day. Admission to intubation time interval was 0.91±0.99, 3.12±1.95, 4.09±2.44, and 4.74±2.62 days, respectively (p<0.001).
The results of this study suggest that the use of etomidate may be associated with higher mortality in COVID-19 patients. Further studies are needed to verify the results of this study.